Investec Bank Plc has filed a Form 8.5 regulatory disclosure revealing trading activity in Advanced Medical Solutions Group Plc (AMS.L) shares on 10th August 2026.
The disclosure was made under Rule 8.5 of the Takeover Code, which governs public dealing disclosures by exempt principal traders with recognised intermediary status acting in a client-serving capacity.
Investec Bank Plc is identified in the filing as advisor and joint broker to Advanced Medical Solutions Group Plc, establishing its connected party status in relation to the disclosure.
The trading activity recorded on 10th August 2026 involved both purchases and sales of ordinary shares in Advanced Medical Solutions Group across a narrow price range.
On the purchase side, Investec acquired a total of 85,178 ordinary shares, with prices ranging from a low of 280.5p to a high of 280.75p per unit.
Sales activity was notably larger in volume, with 124,380 ordinary shares sold at prices ranging between 280.5p and 281.75p per unit during the same session.
The combined trading volumes across both purchases and sales reflect active client-serving activity by Investec in its role as a recognised intermediary during the period in question.
No cash-settled derivative transactions, stock-settled derivative transactions, or options activity was reported as part of this regulatory filing by Investec Bank Plc.
The filing confirms that no indemnity arrangements, option agreements, or any formal or informal understandings relating to relevant securities were in place that could constitute an inducement to deal or refrain from dealing.
Similarly, no agreements or arrangements relating to voting rights or the future acquisition or disposal of securities referenced by any derivative were disclosed as part of the submission.
The disclosure was formally dated 11th August 2026, with contact listed for the filing provided as Abhishek Gawde, reachable by telephone at +91-9923757332.
Regulatory disclosures of this nature under Rule 8 of the Takeover Code are required to be submitted to a recognised Regulatory Information Service to maintain transparency during offer periods.
